Rigel Pharmaceuticals was developing a new drug for the treatment of rheumatoid arthritis. On December 13, 2007, Rigel issued a press release, which was attached to a Form 8-K filed with the SEC touting the positive summary results of a then-recently-completed clinical trial. Based on this, Rigel filed to offer common stock,and referenced the December 13, 2007 Form 8-K. After selling five million shares, Rigel presented the full results of the trial which contained adverse information omitted from the Form 8-K. Rigel's stock price plunged 38% in a single day.

Headquartered in Edinburgh, Scotland, The Royal Bank of Scotland Group operates in the United Kingdom, the United States, and internationally through its two principal subsidiaries, the Royal Bank and NatWest. Both the Royal Bank and NatWest are major United Kingdom-based clearing banks. The Royal Bank of Scotland Group offered shares by means of a prospectus that contained both material misstatements and omissions.

KSF Notifies Insight Enterprises, Inc. Investors with Losses Greater Than $250,000 of Lead Plaintiff Application Deadline in Securities Fraud Class Action Lawsuit

INVESTOR ALERT: Former Attorney General of Louisiana Charles C. Foti, Jr. and KSF Notify Sequenom, Inc. Investors of Lead Plaintiff Application Deadline in Securities Fraud Class Action Lawsuit – SQNM

INVESTOR ALERT: Former Attorney General of Louisiana Charles C. Foti, Jr. and KSF Notify Matrixx Initiatives, Inc. Investors of The Pendency of Class Action Lawsuit And Encourage Investors With Losses in Excess of $300,000 to Inquire About Lead Plaintiff Status - MTXX